What issue did the Court consider in Matrixx Initiatives, Inc.v. Siracusano?

a. The Court reviewed the scienter of Siracusano in thecase.

b. The Court examined whether Matrixx elected not to disclosethe reports of adverse events with the drug Zicam because theyunderstood their likely effect on the market thus meeting themateriality requirement under Section 10(b) of the Securities Actof 1934.

c. The Court determined whether the drug Zicam causedanosmia.

d. The Court studied the FDA approval of Zicam as a drug.